On average, equities analysts expect that Trevena will post ($1.72) earnings per share for the current year.
At the end of December 2016 reporting period, 48 institutional holders increased their position in Trevena, Inc.
Jefferies Group LLC reiterated their buy rating on shares of Trevena, Inc. Zacks Investment Research's EPS averages are an average based on a survey of sell-side research firms that cover Trevena.
Trevena, Inc. (NASDAQ:TRVN) reached 1.24% versus a 1-year low price of $3.23. The Q.i. value may help identify companies that are undervalued. Trevena had a negative net margin of 841.00% and a negative return on equity of 66.50%.
A number of other brokerages have also recently issued reports on TRVN. FBR & Co restated an "outperform" rating and issued a $8.00 target price (down from $13.00) on shares of Trevena in a research note on Wednesday, February 22nd.
10/03/2016 - Brean Capital began new coverage on Trevena Inc giving the company a "buy" rating. Aegis reiterated a "buy" rating and issued a $14.00 price objective on shares of Trevena in a research report on Monday. Finally, Zacks Investment Research downgraded Trevena from a "hold" rating to a "sell" rating in a research report on Wednesday, January 11th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have given a buy rating to the company. The company presently has a consensus rating of "Buy" and an average price target of $11.73. If you are accessing this story on another publication, it was illegally copied and republished in violation of USA & global trademark and copyright legislation. The correct version of this story can be viewed at https://www.themarketsdaily.com/2017/04/19/0-53-eps-expected-for-trevena-inc-trvn-this-quarter.html.
Shares of Trevena (NASDAQ:TRVN) opened at 7.03 on Thursday.
Multiple company employees have indulged in significant insider trading. The company has a 50-day moving average of $6.82 and a 200-day moving average of $6.38. The firm's market capitalization is $367.91 million. They now have a Dollars 10 price target on the stock. Northpointe Capital LLC boosted its position in shares of Trevena by 88.9% in the third quarter. The brokerage now has a $11.00 target price on the biopharmaceutical company's stock. Russell Investments Group Ltd. bought a new position in shares of Trevena during the fourth quarter worth $483,000. Finally, State Street Corp boosted its stake in Trevena by 3.9% in the fourth quarter. State Street Corp now owns 706,305 shares of the biopharmaceutical company's stock valued at $4,154,000 after buying an additional 26,620 shares during the period.
03/08/2017 - Trevena Inc had its "buy" rating reiterated by analysts at Needham & Company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). The Company's product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases.